Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $163.8 million.

  • Voyager Therapeutics' Short-term Investments fell 2964.76% to $163.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.8 million, marking a year-over-year decrease of 2964.76%. This contributed to the annual value of $195.3 million for FY2024, which is 2051.17% up from last year.
  • As of Q3 2025, Voyager Therapeutics' Short-term Investments stood at $163.8 million, which was down 2964.76% from $171.7 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Short-term Investments ranged from a high of $294.9 million in Q2 2024 and a low of $5.0 million during Q1 2023
  • In the last 5 years, Voyager Therapeutics' Short-term Investments had a median value of $69.7 million in 2022 and averaged $111.2 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first crashed by 8571.8% in 2023, then surged by 503699.18% in 2024.
  • Over the past 5 years, Voyager Therapeutics' Short-term Investments (Quarter) stood at $15.1 million in 2021, then skyrocketed by 31.66% to $19.9 million in 2022, then soared by 714.89% to $162.1 million in 2023, then grew by 20.51% to $195.3 million in 2024, then fell by 16.13% to $163.8 million in 2025.
  • Its Short-term Investments was $163.8 million in Q3 2025, compared to $171.7 million in Q2 2025 and $161.3 million in Q1 2025.